Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2005 | Original Article

Early restaging whole-body ¹⁸F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma

Authors: Ruoh-Fang Yen, Tony Hsiu-Hsi Chen, Lai-Lei Ting, Kai-Yuan Tzen, Mei-Hsiu Pan, Ruey-Long Hong

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2005

Abstract

Purpose

This study was undertaken to evaluate the utility of whole-body ¹⁸F-FDG PET in monitoring therapeutic effect during induction chemotherapy (IC) and in predicting prognosis in patients with locoregionally advanced nasopharyngeal carcinoma (NPC).

Methods

Fifty patients who had histologically proven, locoregionally advanced NPC without distant metastasis and had received IC were recruited in this study. The study cohort consisted of 19 females and 31 males (age 17–72 years, mean 45.9±11.9). Whole-body ¹⁸F-FDG PET was performed in each patient after completion of one (33 patients) or two (17 patients) courses of IC. Each patient was restaged on the basis of the ¹⁸F-FDG PET results. Patients who were downstaged to stage I or II were classified as major responders; the rest were classified as non-major responders.

Results

Only 1 of the 23 major responders subsequently developed local recurrence. At the time of data analysis, all major responders were alive; by contrast, of the 27 non-major responders, 15 had locoregional recurrence or distant metastasis and nine had died (seven of NPC and two of treatment-related complications). Kaplan-Meier survival analysis showed significantly longer recurrence-free survival and overall survival in major responders (56.4±9.2 and 58.1±2.2 months) as compared with non-major responders (33.7±23.2 and 44.7±20.0 months), with p<0.0001 and p=0.0024, respectively.

Conclusion

The results of this study suggest that early restaging by a single whole-body ¹⁸F-FDG PET scan after the first or second course of IC is useful for predicting therapeutic response and outcome in patients with locoregionally advanced NPC.

Huang DP. Epidemiology of nasopharyngeal carcinoma. Ear Nose Throat J 1990;69:222–5PubMed

Oh JL, Vokes EE, Kies MS, Mittal BB, Witt ME, Weichselbaum RR, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003;14:564–9

Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2000;20:1845–52CrossRefPubMed

Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:4305–13PubMed

Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 1995;31A:1924–7CrossRefPubMed

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [¹⁸F]-fluorodexoyglucose and positron emission tomography: review and 1999 EORTC recommendation. Eur J Cancer 1999;35:1773–82CrossRefPubMed

Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([¹⁸F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is[¹⁸F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414–9PubMed

Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with ¹⁸F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 2002;13:1356–63

Kosgakoglu L, Cloemen M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002;43:1018–27PubMed

10.

Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470–7PubMed

11.

Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931–8PubMed

12.

Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron tomography using [¹⁸F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1679–88

13.

Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [¹⁸F]fluorodeoxyglucose for monitoring to primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–95PubMed

14.

Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [¹⁸F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002;38:375–9CrossRefPubMed

15.

Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999;40:1637–43

16.

Franzius C, Bielack S, Flege S, Sciuk J, Jürgens H, Schober O. Prognostic significance of ¹⁸F-FDG and^99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002;43:1012–7PubMed

17.

Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058–65PubMed

18.

Brücher B, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300–9

19.

Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction chemotherapy in locally advanced esophageal cancer. Ann Oncol 2002;13:361–8

20.

Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604–10CrossRefPubMed

21.

Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy to quantitative assessment of glucose use. J Clin Oncol 2003;21:2651–7CrossRefPubMed

22.

Lowe VJ, Dunphy FR, Varvares M, Kim H, Wittry M, Dunphy CH, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck 1997;19:666–74CrossRefPubMed

23.

Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004;45:56–68PubMed

24.

Reisser C, Haberkom U, Dimitrakopulou-Strauss A, Seifert E, Strauss LG. Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg 1995;121:272–6PubMed

25.

Kaplan ES, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;58:457–81

26.

Higashi K, Anaira CC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? in vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993;34:414–9PubMed

27.

Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348–52

28.

Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–11PubMed

29.

Yen RF, Chen ML, Liu FY, Ko SC, Chang YL, Chieng PU, et al. False-positive 2-[F-18]-fluoro-2-deoxy-d-glucose positron emission tomography studies for evaluation of focal pulmonary abnormalities. J Formosan Med Assoc 1998;97:642–5PubMed

30.

Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004;231:65–72PubMed

31.

Goerres GW, von Schulthess GK, Steinert HC. Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med 2004;45:66S–71SPubMed

32.

Dressel S, Grammerstorff J, Schwenzer K, Brinkbaumer K, Schmid R, Pfluger T, et al. [¹⁸F]FDG imaging of head and neck tumours: comparison of hybrid PET and morphological methods. Eur J Nucl Med Mol Imaging 2003;30:995–1003CrossRefPubMed

33.

Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Schwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 1997;24:1091–8PubMed

Title: Early restaging whole-body 18F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma
Authors: Ruoh-Fang Yen
Tony Hsiu-Hsi Chen
Lai-Lei Ting
Kai-Yuan Tzen
Mei-Hsiu Pan
Ruey-Long Hong
Publication date: 01-10-2005
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2005
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-1837-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Early restaging whole-body ¹⁸F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2005

Relative roles of bone scintigraphy and positron emission tomography in assessing the treatment response of bone metastases

Perfusion abnormality of the caudate nucleus in patients with paroxysmal kinesigenic choreoathetosis

Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney?

Oral contrast medium in PET/CT: should you or shouldn’t you?

Absorbed whole-body doses from whole-body CT scan examinations: can the observations relating to screening of healthy individuals be extrapolated to the use of whole-body CT in PET/CT hybrid machines?

PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients